Highest-materiality recent filing
Charles River Q1 GAAP EPS $(0.30), non-GAAP $2.06; reaffirms FY2026 guidance
Q1 revenue $995.8M (+1.2% reported, -1.5% organic); GAAP loss $(0.30) vs $0.50 prior year.
Charles River to divest CDMO/Cell Solutions and European Discovery assets; updates 2026 guidance
Definitive agreement to sell CDMO and Cell Solutions to GI Partners for future performance-based payments; $143M 2025 revenue.
Charles River appoints Glenn Coleman as CFO, effective April 6, 2026
Glenn Coleman, 58, joins from Premier, Inc. with 30+ years of financial leadership.
Charles River Labs Q4 revenue $994M, GAAP loss $5.62; sees 2026 non-GAAP EPS $10.70-$11.20
Q4 GAAP loss per share $(5.62) from $994.2M revenue (-0.8% YoY); non-GAAP EPS $2.39 (-10.2%).
Preliminary Q4 DSA net book-to-bill ~1.1x, driven by improved demand from small/mid biotech and global biopharma in Q4.
James C. Foster to step down as CEO and Chairman; Birgit Girshick (COO) to become CEO effective May 5, 2026.
Charles River Labs reports improving DSA book-to-bill trends, encouraged by momentum since mid-2025
DSA net book-to-bill has improved each month since Q3 2025 started.
SEC concludes investigation into Charles River; no enforcement action recommended
SEC Division of Enforcement notified company on Nov 14, 2025, that it will not recommend enforcement action.
Charles River Q3 revenue $1.00B (-0.5% YoY); GAAP EPS $1.10, non-GAAP $2.43
Organic revenue declined 1.6%; DSA -3.1%, Manufacturing -5.1%, offset by RMS +6.5%.
CFO Flavia Pease resigns; CAO Michael Knell named interim CFO; FY2025 guidance reaffirmed
Flavia H. Pease resigns as CFO effective September 29, 2025, to pursue another opportunity; no disagreements with company.
Charles River Q2 non-GAAP EPS $3.12 beats; raises 2025 guidance; DOJ closes NHP probe
Q2 revenue $1.032B (+0.6% reported; organic -0.5%); GAAP EPS $1.06, non-GAAP EPS $3.12 up 11.4% YoY.
CRL enters cooperation with Elliott, adds 4 directors, launches strategic review
Four new directors (Steven Barg, Abe Ceesay, Mark Enyedy, Paul Graves) to join board after May 20 annual meeting.
Charles River Q1 revenue down 2.7% to $984.2M; raises FY2025 guidance
GAAP EPS $0.50 vs $1.30 YoY; Non-GAAP EPS $2.34 vs $2.27, up 3.1%.
Q4 revenue $1.00B (-1.1% YoY); non-GAAP EPS $2.66 (+8.1%); GAAP loss $(4.22) from $215M Biologics Solutions goodwill impairment.
Expects 2025 revenue to decline organically in similar range as estimated 2024; DSA demand consistent with H2 2024.
Charles River amends credit agreement, cuts revolver to $2B, extends to 2029
Revolving commitments reduced from $3B to $2B; maturity extended to December 13, 2029.
Revenue $1.01B, down 1.6% YoY (organic -2.7%); GAAP EPS $1.33, non-GAAP EPS $2.59.
Charles River Q2 revenue falls 3.2% to $1.03B; slashes FY24 guidance on weak demand
GAAP EPS $1.74 (-7.9% YoY); Non-GAAP EPS $2.80 (+4.1%), Non-GAAP net income $144.9M (+4.8%).
Q4 GAAP EPS $3.62 vs $3.65 YoY; non-GAAP EPS $2.46 vs $2.98, down 17.4%.
Charles River Q3 results beat; narrows and raises non-GAAP EPS guidance for 2023
Q3 revenue $1.03B (+3.8% YoY); GAAP EPS $1.69 (-10.1%), non-GAAP EPS $2.72 (+3.4%).
Charles River Q2 revenue up 8.9% to $1.06B; GAAP EPS $1.89, non-GAAP $2.69; guidance narrowed upward
Revenue $1.06B (+8.9% YoY, organic +11.2%); DSA segment revenue $663.5M (+12.1%) drove growth.
Charles River Q1 revenue $1.03B, +12.6% YoY; raises organic growth guidance to 5.0-7.5%
GAAP EPS $2.01 (+11% YoY); non-GAAP EPS $2.78 (+1.1% YoY); net income $103.1M.
Q4 GAAP EPS $3.65, non-GAAP EPS $2.98; full-year GAAP EPS $9.48, non-GAAP EPS $11.12.
Charles River addresses NHP supply disruption risk following DOJ charges against Cambodian supplier
Company not named in DOJ proceedings; no direct contracts with indicted Cambodian supplier.
Charles River Q3 revenue $989.2M (+10.4% YoY); raises guidance, plans Avian Vaccine sale for ~$170M
Q3 revenue $989.2M (+10.4% YoY, organic +15.3%); GAAP EPS $1.88 (-6.5%), non-GAAP EPS $2.63 (-2.6%).
Charles River Q2 revenue $973.1M (+6.4% YoY); non-GAAP EPS $2.77 (+6.1%); cuts FY22 guidance
GAAP EPS $2.13 vs $1.72 Q2 2021; non-GAAP EPS $2.77 vs $2.61.
Charles River lowers Q2 2022 revenue and EPS outlook, cites FX and CDMO headwinds
Q2 reported revenue growth guidance cut from low-double-digit to high-single-digit YoY; non-GAAP EPS growth cut from mid- to high-single-digit to low- to mid-single-digit.
Charles River Q1 revenue $913.9M (+10.8%), GAAP EPS $1.81, non-GAAP EPS $2.75
Q1 revenue $913.9M (+10.8% YoY); organic growth 9.4%; GAAP net income $93.0M (+51.2%); non-GAAP net income $141.1M (+9.3%).
Charles River Labs appoints Flavia Pease as CFO; David Smith retires to Senior Advisor
Flavia Pease named Corporate EVP and CFO effective after Q1 2022 10-Q filing (~early May 2022).
Charles River Q4 rev $905.1M (+14.4%); reaffirms 2022 guidance with non-GAAP EPS $11.50-$11.75
Q4 GAAP EPS $2.67 vs $2.81 prior year (-5%); non-GAAP EPS $2.49 vs $2.39 (+4.2%).
Charles River previews 2022: low-double-digit organic revenue growth, margin expansion, 9% capex
Expects low-double-digit organic revenue growth in 2022 driven by sustained robust demand.
Charles River Q3 revenue $895.9M (+20.5% YoY); non-GAAP EPS $2.70; updates 2021 guidance
Revenue $895.9M, +20.5% YoY; organic growth 13.6% with contributions from all three segments.
Charles River Q2 revenue $914.6M (+34% YoY); raises 2021 guidance above prior estimates
Revenue $914.6M, +34% YoY (organic +24.1%); GAAP EPS $1.72, non-GAAP EPS $2.61.
the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election
the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election
the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election
On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).
On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).
the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election
On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).
On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).
Following the size increase of the Board, the Board filled the vacancy and appointed Ms. Reshema Kemps-Polanco to the Board.
William D. Barbo, its Corporate Executive Vice President and Chief Commercial Officer, will retire from the Company at the end of 2024 after a distinguished, 42-year career with the Company.
Kristen Eisenhauer is assuming the role of Senior Vice President, Chief Commercial Officer.
Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board.
Max materiality 0.85 · Median 0.70 · Most common event earnings